Pfizer Gains FDA Approval for Besponsa in Pediatric Relapsed or Refractory ALL Patients

Pfizer's inotuzumab ozogamicin (Besponsa) has cleared FDA review for pediatric patients aged one year and older with relapsed or refractory CD22-positive B-cell precursor acute lymphoblastic leukemia, extending an indication previously held for adults into a population where treatment options remain limited. For regulatory affairs teams, the approval is a concrete example of how priority review and orphan drug designation compress timelines for serious pediatric oncology indications under PREA requirements.

Efficacy data came from a multicenter, single-arm, open-label study enrolling 53 pediatric patients. The primary dose evaluated was 1.8 mg/m² per cycle, administered in three divided doses on Days 1, 8, and 15. Across all patients, 42% (22/53; 95% CI: 28.1, 55.9%) achieved complete remission, with a median CR duration of 8.2 months. Minimal residual disease negativity among patients achieving CR reached 95.5% by flow cytometry and 86.4% by RQ-PCR, figures that carry weight in the context of a heavily pretreated pediatric population receiving a median of two treatment cycles.

The safety profile warrants close attention for pharmacovigilance and medical affairs teams. Adverse reactions occurring in 20% or more of patients included thrombocytopenia, pyrexia, anemia, vomiting, infection, hemorrhage, neutropenia, nausea, leukopenia, febrile neutropenia, increased transaminases, abdominal pain, and headache. The transaminase signal is consistent with the hepatotoxicity risk already documented in the adult label and will require corresponding risk management considerations in pediatric clinical settings.

From a dosing-protocol standpoint, Cycle 1 runs three weeks at the 1.8 mg/m² level but may be extended to four weeks if the patient achieves complete remission or complete remission with incomplete hematologic recovery, or to allow toxicity resolution. Subsequent cycle dosing follows prescribing information guidance, a detail manufacturing and clinical supply teams should factor into demand forecasting for this patient segment.

The application's receipt of both priority review and orphan drug designation positions it as a reference case for regulatory strategy teams building pediatric oncology dossiers, particularly those navigating the intersection of 21 CFR Part 312 pediatric study requirements and FDA's expedited program framework outlined in the Guidance for Industry on Expedited Programs for Serious Conditions. Serious adverse events should be reported through FDA's MedWatch system or by calling 1-800-FDA-1088.

The MRD negativity rate of 95.5% in CR patients will serve as a measurable benchmark as post-marketing data accumulates across broader pediatric use.

Source: FDA Oncology Center of Excellence via FDA.gov What's New: Drugs RSS Feed, November 7, 2026. Approval date: March 6, 2024.